In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer-CuraGen: Gambling They Can Improve the Odds

Executive Summary

Rather than spending to build the requisite infrastructure for a small-molecule program, CuraGen decided to partner, with Bayer, in a deal targeting metabolic disorders. But merely licensing out its small-molecule targets for current cash sells the future short which is why CuraGen was willing to forego cash payments in its deal. Instead, CuraGen is providing a capped $590 million in unreimbursed value to the program in return for what could be up to 44% of the profits from any one product. The only Bayer cash going into CuraGen's pocket is $135 million (albeit mostly equity) from a separate pharmacogenomics/toxicogenomics deal, without which it's questionable whether CuraGen could have afforded the Bayer alliance or whether Bayer itself would have agreed to it. The key point: Bayer aims to use the CuraGen pharmacogenomics technology to increase the predictability of its entire R&D effort and was thus willing to forego a significant piece of the end proceeds from the metabolic disease program.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts